Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27874496 | 0.82 | MAPK1 (0.51) | MAPTTP53ALDH1A1NPC1RAB9A | |
| SCHEMBL7168897 | 0.77 | MAPT (0.64) | MAPTTP53KMT2AALDH1A1CYP1A2 | |
| SCHEMBL10419309 | 0.75 | MAPT (0.45) | MAPTTP53KMT2AALDH1A1CYP1A2 | |
| SCHEMBL5642066 | 0.74 | CYP1A2 (0.64) | MAPTKMT2AALDH1A1CYP1A2NPC1 | |
| SCHEMBL9165375 | 0.72 | ALDH1A1 (0.44) | MAPTTP53KMT2AALDH1A1CYP1A2 | |
| SCHEMBL13629843 | 0.71 | — | — | |
| SCHEMBL19475102 | 0.71 | ALDH1A1 (0.55) | MAPTTP53KMT2AALDH1A1NPC1 | |
| SCHEMBL7429377 | 0.70 | CYP1A2 (0.55) | MAPTTP53KMT2AALDH1A1CYP1A2 | |
| SCHEMBL243257 | 0.70 | MAPT (0.50) | MAPTKMT2AALDH1A1CYP1A2NPC1 | |
| SCHEMBL971766 | 0.70 | MAPT (0.50) | MAPTKMT2AALDH1A1CYP1A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114222574-B | Inhibition of USP36 | 瓦洛健康股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-114222574-A | Inhibition of USP36 | 瓦洛健康股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
| CN-103906518-B | Malignant and non-malignant disease treatment using RAS antagonists | 派西斯治疗有限责任公司 | 2020-03-13 | — | — | CN | disclosed |
| CN-107353283-B | The preparation method of 1,2,3- thiadiazoles -5- Carbox amide | 利尔化学股份有限公司 | 2019-11-08 | — | — | CN | disclosed |
| CN-107353283-A | The preparation method of 1,2,3- thiadiazoles -5- Carbox amides | 利尔化学股份有限公司 | 2017-11-17 | — | — | CN | disclosed |
| CN-107250120-A | 1,3, 4-thiadiazol-2-yl-benzamide derivatives as inhibitors of the Wnt signaling pathway | 拜耳制药股份公司 | 2017-10-13 | — | — | CN | disclosed |
| US-20170081320-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-23 | — | — | US | disclosed |
| US-9173861-B2 | Thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2379518-B1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2014-05-07 | — | — | EP | disclosed |
| EP-0973770-A1 | FUNGICIDAL METHOXIMINOMETHYLDIOXAZINES | BAYER AG (DE) | 2000-01-26 | — | — | EP | disclosed |
| US-5977373-A | Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents | PHARMACIA & UPJOHN COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1999002525-A1 | THIADIAZOLYL AND OXADIAZOLYL PHENYL OXAZOLIDINONE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-01-21 | — | — | WO | disclosed |
| WO-1998045289-A1 | FUNGICIDAL METHOXIMINOMETHYLDIOXAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-10-15 | — | — | WO | disclosed |
| EP-0326640-B1 | (1R,5S,6S)-2-SUBSTITUTED THIO-6 (R)-1-HYDROXYETHYL -1-METHYL-CARBAPENEM - CARBOXYLIC ACID DERIVATIVES | LEDERLE (JAPAN) LTD. (JP) | 1993-04-28 | — | — | EP | disclosed |
| EP-0326640-A1 | (1R,5S,6S)-2-substituted thio-6 (R)-1-hydroxyethyl -1-methyl-carbapenem - carboxylic acid derivatives | LEDERLE (JAPAN) LTD. (JP) | 1989-08-09 | — | — | EP | disclosed |
| US-4746736-A | THIENAMYCINS, BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1988-05-24 | — | — | US | disclosed |
| US-4732977-A | BACTERICIDES | BRISTOL MYERS COMPANY (US) | 1988-03-22 | — | — | US | disclosed |
| US-4644061-A | Carbapenem antibiotics | BRISTOL-MYERS COMPANY (US) | 1987-02-17 | — | — | US | disclosed |
| CN-86102987-A | The production method of carbapeneme | — | 1986-11-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081320-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | MAPT 4695/4885TP53 3810/4885KMT2A 3462/4885 |
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | EPOR, EZR, CD47 | MAPT 4222/4885TP53 2273/4885KMT2A 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.